Novartis and Eisai end Japan COPD alliance
This article was originally published in Scrip
Novartis and Eisai have decided to discontinue their co-promotion alliance in Japan for three Novartis inhaled products for the treatment of chronic obstructive pulmonary disease (COPD), following a review of the tie-up and sales strategies for the products.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.